Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Research Report 2023

Publication ID:

PB510232018

Publication Date:

October 16, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Noninvasive cancer diagnostics and technology refer to methods and devices used to detect and diagnose cancer without the need for invasive procedures such as surgery or biopsies. These approaches aim to minimize patient discomfort, risk, and recovery time, while providing accurate and timely cancer detection.
The global Noninvasive Cancer Diagnostics and Technology market is projected to reach US$ 2328.5 million in 2029, increasing from US$ 1430 million in 2022, with the CAGR of 7.3% during the period of 2023 to 2029.
The global noninvasive cancer diagnostics and technology market refers to the market for diagnostic tools and technologies that are used to detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. These noninvasive methods are typically less painful, less risky, and offer quicker results compared to traditional diagnostic techniques.
The demand for noninvasive cancer diagnostics and technology has been increasing worldwide due to the rising prevalence of cancer and the need for early detection and accurate diagnosis. Noninvasive methods can include imaging techniques, liquid biopsies, molecular testing, genetic testing, and other innovative technologies.
Imaging techniques such as MRI, CT scans, ultrasound, and PET scans play a significant role in noninvasive cancer diagnosis by providing detailed images of the affected area. These imaging technologies help identify the location, size, and extent of tumors, enabling oncologists to make informed decisions regarding treatment plans.
Liquid biopsies have gained considerable attention in recent years for their ability to detect cancer-related biomarkers in blood samples. These tests analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other components present in the bloodstream, providing valuable information about the presence of cancer, its stage, and potential treatment options.
Molecular testing and genetic testing also contribute to noninvasive cancer diagnostics by analyzing genetic mutations and alterations in tumors. These tests help identify specific genetic markers associated with different types of cancer, allowing for personalized treatment approaches and monitoring of therapy effectiveness.
The global noninvasive cancer diagnostics and technology market is highly competitive and fragmented, with numerous companies specializing in different diagnostic modalities. Key players in the market include manufacturers of imaging equipment, diagnostic laboratories, biotechnology companies, and pharmaceutical companies.
North America currently dominates the market, driven by advanced healthcare infrastructure, increasing cancer prevalence, and high adoption of novel diagnostic technologies. Europe is also a significant market, with a focus on early cancer detection and personalized medicine. Furthermore, emerging markets in Asia Pacific and Latin America are witnessing rapid growth due to improving healthcare infrastructure, rising awareness, and government initiatives to combat cancer.
Factors driving market growth include technological advancements, increasing research and development activities, a growing emphasis on personalized medicine, and the rising demand for noninvasive diagnostic techniques. However, high costs associated with advanced diagnostic tools and limited reimbursement coverage in some regions could hinder market growth.
In conclusion, the global noninvasive cancer diagnostics and technology market is expanding due to the demand for early detection, accurate diagnosis, and personalized treatment options. Noninvasive diagnostic techniques, such as imaging, liquid biopsies, and genetic testing, offer significant advantages over invasive procedures and are expected to play a crucial role in the future of cancer diagnosis and treatment.The global noninvasive cancer diagnostics and technology market refers to the market for diagnostic tools and technologies that are used to detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. These noninvasive methods are typically less painful, less risky, and offer quicker results compared to traditional diagnostic techniques.
The demand for noninvasive cancer diagnostics and technology has been increasing worldwide due to the rising prevalence of cancer and the need for early detection and accurate diagnosis. Noninvasive methods can include imaging techniques, liquid biopsies, molecular testing, genetic testing, and other innovative technologies.
Imaging techniques such as MRI, CT scans, ultrasound, and PET scans play a significant role in noninvasive cancer diagnosis by providing detailed images of the affected area. These imaging technologies help identify the location, size, and extent of tumors, enabling oncologists to make informed decisions regarding treatment plans.
Liquid biopsies have gained considerable attention in recent years for their ability to detect cancer-related biomarkers in blood samples. These tests analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other components present in the bloodstream, providing valuable information about the presence of cancer, its stage, and potential treatment options.
Molecular testing and genetic testing also contribute to noninvasive cancer diagnostics by analyzing genetic mutations and alterations in tumors. These tests help identify specific genetic markers associated with different types of cancer, allowing for personalized treatment approaches and monitoring of therapy effectiveness.
The global noninvasive cancer diagnostics and technology market is highly competitive and fragmented, with numerous companies specializing in different diagnostic modalities. Key players in the market include manufacturers of imaging equipment, diagnostic laboratories, biotechnology companies, and pharmaceutical companies.
North America currently dominates the market, driven by advanced healthcare infrastructure, increasing cancer prevalence, and high adoption of novel diagnostic technologies. Europe is also a significant market, with a focus on early cancer detection and personalized medicine. Furthermore, emerging markets in Asia Pacific and Latin America are witnessing rapid growth due to improving healthcare infrastructure, rising awareness, and government initiatives to combat cancer.
Factors driving market growth include technological advancements, increasing research and development activities, a growing emphasis on personalized medicine, and the rising demand for noninvasive diagnostic techniques. However, high costs associated with advanced diagnostic tools and limited reimbursement coverage in some regions could hinder market growth.
In conclusion, the global noninvasive cancer diagnostics and technology market is expanding due to the demand for early detection, accurate diagnosis, and personalized treatment options. Noninvasive diagnostic techniques, such as imaging, liquid biopsies, and genetic testing, offer significant advantages over invasive procedures and are expected to play a crucial role in the future of cancer diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Noninvasive Cancer Diagnostics and Technology market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
BIOVIEW Inc.
Affymetrix Inc.
Precision Therapeutics
Digene Corporation
A&G Pharmaceutical
Gen-Probe Incorporated
AVIVA Biosciences Corporation
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
Guardant Health
Exact Sciences
GRAIL
Konica Minolta
Illumina
Biocept
Segment by Type
Immunoassays
Molecular Diagnostics
Clinical Chemistry
Other
Segment by Application
Medical Device Manufacturing Companies
Hospitals and Clinics
Oncology Laboratories
Private Research Institutions
Academic Institutions
Pharmaceutical Companies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Noninvasive Cancer Diagnostics and Technology report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immunoassays
1.2.3 Molecular Diagnostics
1.2.4 Clinical Chemistry
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Medical Device Manufacturing Companies
1.3.3 Hospitals and Clinics
1.3.4 Oncology Laboratories
1.3.5 Private Research Institutions
1.3.6 Academic Institutions
1.3.7 Pharmaceutical Companies
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Perspective (2018-2029)
2.2 Noninvasive Cancer Diagnostics and Technology Growth Trends by Region
2.2.1 Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Noninvasive Cancer Diagnostics and Technology Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Noninvasive Cancer Diagnostics and Technology Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Noninvasive Cancer Diagnostics and Technology 麻豆原创 Dynamics
2.3.1 Noninvasive Cancer Diagnostics and Technology Industry Trends
2.3.2 Noninvasive Cancer Diagnostics and Technology 麻豆原创 Drivers
2.3.3 Noninvasive Cancer Diagnostics and Technology 麻豆原创 Challenges
2.3.4 Noninvasive Cancer Diagnostics and Technology 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Noninvasive Cancer Diagnostics and Technology Players by Revenue
3.1.1 Global Top Noninvasive Cancer Diagnostics and Technology Players by Revenue (2018-2023)
3.1.2 Global Noninvasive Cancer Diagnostics and Technology Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Noninvasive Cancer Diagnostics and Technology Revenue
3.4 Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Concentration Ratio
3.4.1 Global Noninvasive Cancer Diagnostics and Technology 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Noninvasive Cancer Diagnostics and Technology Revenue in 2022
3.5 Noninvasive Cancer Diagnostics and Technology Key Players Head office and Area Served
3.6 Key Players Noninvasive Cancer Diagnostics and Technology Product Solution and Service
3.7 Date of Enter into Noninvasive Cancer Diagnostics and Technology 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Noninvasive Cancer Diagnostics and Technology Breakdown Data by Type
4.1 Global Noninvasive Cancer Diagnostics and Technology Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Noninvasive Cancer Diagnostics and Technology Forecasted 麻豆原创 Size by Type (2024-2029)
5 Noninvasive Cancer Diagnostics and Technology Breakdown Data by Application
5.1 Global Noninvasive Cancer Diagnostics and Technology Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Noninvasive Cancer Diagnostics and Technology Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size (2018-2029)
6.2 North America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2018-2023)
6.4 North America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size (2018-2029)
7.2 Europe Noninvasive Cancer Diagnostics and Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2018-2023)
7.4 Europe Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Noninvasive Cancer Diagnostics and Technology 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size (2018-2029)
9.2 Latin America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Noninvasive Cancer Diagnostics and Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Noninvasive Cancer Diagnostics and Technology 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BIOVIEW Inc.
11.1.1 BIOVIEW Inc. Company Detail
11.1.2 BIOVIEW Inc. Business Overview
11.1.3 BIOVIEW Inc. Noninvasive Cancer Diagnostics and Technology Introduction
11.1.4 BIOVIEW Inc. Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.1.5 BIOVIEW Inc. Recent Development
11.2 Affymetrix Inc.
11.2.1 Affymetrix Inc. Company Detail
11.2.2 Affymetrix Inc. Business Overview
11.2.3 Affymetrix Inc. Noninvasive Cancer Diagnostics and Technology Introduction
11.2.4 Affymetrix Inc. Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.2.5 Affymetrix Inc. Recent Development
11.3 Precision Therapeutics
11.3.1 Precision Therapeutics Company Detail
11.3.2 Precision Therapeutics Business Overview
11.3.3 Precision Therapeutics Noninvasive Cancer Diagnostics and Technology Introduction
11.3.4 Precision Therapeutics Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.3.5 Precision Therapeutics Recent Development
11.4 Digene Corporation
11.4.1 Digene Corporation Company Detail
11.4.2 Digene Corporation Business Overview
11.4.3 Digene Corporation Noninvasive Cancer Diagnostics and Technology Introduction
11.4.4 Digene Corporation Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.4.5 Digene Corporation Recent Development
11.5 A&G Pharmaceutical
11.5.1 A&G Pharmaceutical Company Detail
11.5.2 A&G Pharmaceutical Business Overview
11.5.3 A&G Pharmaceutical Noninvasive Cancer Diagnostics and Technology Introduction
11.5.4 A&G Pharmaceutical Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.5.5 A&G Pharmaceutical Recent Development
11.6 Gen-Probe Incorporated
11.6.1 Gen-Probe Incorporated Company Detail
11.6.2 Gen-Probe Incorporated Business Overview
11.6.3 Gen-Probe Incorporated Noninvasive Cancer Diagnostics and Technology Introduction
11.6.4 Gen-Probe Incorporated Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.6.5 Gen-Probe Incorporated Recent Development
11.7 AVIVA Biosciences Corporation
11.7.1 AVIVA Biosciences Corporation Company Detail
11.7.2 AVIVA Biosciences Corporation Business Overview
11.7.3 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics and Technology Introduction
11.7.4 AVIVA Biosciences Corporation Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.7.5 AVIVA Biosciences Corporation Recent Development
11.8 Quest Diagnostics Incorporated
11.8.1 Quest Diagnostics Incorporated Company Detail
11.8.2 Quest Diagnostics Incorporated Business Overview
11.8.3 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics and Technology Introduction
11.8.4 Quest Diagnostics Incorporated Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.8.5 Quest Diagnostics Incorporated Recent Development
11.9 Laboratory Corporation of America Holdings
11.9.1 Laboratory Corporation of America Holdings Company Detail
11.9.2 Laboratory Corporation of America Holdings Business Overview
11.9.3 Laboratory Corporation of America Holdings Noninvasive Cancer Diagnostics and Technology Introduction
11.9.4 Laboratory Corporation of America Holdings Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.9.5 Laboratory Corporation of America Holdings Recent Development
11.10 Guardant Health
11.10.1 Guardant Health Company Detail
11.10.2 Guardant Health Business Overview
11.10.3 Guardant Health Noninvasive Cancer Diagnostics and Technology Introduction
11.10.4 Guardant Health Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.10.5 Guardant Health Recent Development
11.11 Exact Sciences
11.11.1 Exact Sciences Company Detail
11.11.2 Exact Sciences Business Overview
11.11.3 Exact Sciences Noninvasive Cancer Diagnostics and Technology Introduction
11.11.4 Exact Sciences Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.11.5 Exact Sciences Recent Development
11.12 GRAIL
11.12.1 GRAIL Company Detail
11.12.2 GRAIL Business Overview
11.12.3 GRAIL Noninvasive Cancer Diagnostics and Technology Introduction
11.12.4 GRAIL Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.12.5 GRAIL Recent Development
11.13 Konica Minolta
11.13.1 Konica Minolta Company Detail
11.13.2 Konica Minolta Business Overview
11.13.3 Konica Minolta Noninvasive Cancer Diagnostics and Technology Introduction
11.13.4 Konica Minolta Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.13.5 Konica Minolta Recent Development
11.14 Illumina
11.14.1 Illumina Company Detail
11.14.2 Illumina Business Overview
11.14.3 Illumina Noninvasive Cancer Diagnostics and Technology Introduction
11.14.4 Illumina Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.14.5 Illumina Recent Development
11.15 Biocept
11.15.1 Biocept Company Detail
11.15.2 Biocept Business Overview
11.15.3 Biocept Noninvasive Cancer Diagnostics and Technology Introduction
11.15.4 Biocept Revenue in Noninvasive Cancer Diagnostics and Technology Business (2018-2023)
11.15.5 Biocept Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

BIOVIEW Inc.
Affymetrix Inc.
Precision Therapeutics
Digene Corporation
A&G Pharmaceutical
Gen-Probe Incorporated
AVIVA Biosciences Corporation
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
Guardant Health
Exact Sciences
GRAIL
Konica Minolta
Illumina
Biocept

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.